Latest news with #NandiniPiramal
Time of India
16-05-2025
- Business
- Time of India
Piramal Pharma to stay away from prescription business in India: Nandini Piramal
Mumbai: Piramal Pharma has no plans to enter domestic prescription formulations business for now, chairperson Nandini Piramal told ET, putting to rest speculations that the company is evaluating acquisitions in this space. The company, however, may consider acquiring over-the-counter (OTC) portfolios or individual brands and products for its India-focused consumer healthcare business , which crossed the strategic revenue milestone of ₹1,000 crore in FY25. It may also evaluate targets in its global complex hospital generics business. Piramal explained that rivals that already have a prescription business would be willing to pay more for an acquisition target as they would get immediate synergies. "So, the amount that they can afford to pay versus wouldn't have that," she said. Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track default , selected Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More Undo Piramal Pharma sold its domestic formulation business to Abbott for $3.8 billion in 2010. On its future growth strategy, the chairperson said the company will continue to focus on organic brownfield expansion in the drug development and manufacturing service business, or Contract Development and Manufacturing Organisation ( CDMO ). Live Events The company is looking at capex of $100-125 million, she said. Talking about the current global headwinds, Piramal said near-term macroeconomic uncertainty and uneven improvement in biotech funding is leading to customers taking more time to decide and place orders, thus leading to lower capacity utilisation in the overseas CDMO sites. However, the company's India sites are running at a healthy utilisation level, she said. "In many of our overseas sites, we have recently made investments and hence their utilisation will gradually pick up as we fill them with new orders," she added. About 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and Japan. On overall future product pipeline, Piramal said there are 31 products in phase 3 trial, 30 in phase 2, and 177 in phase 1. The company posted 8% year-on-year growth in revenue from operations for the fourth quarter of FY25 ended March and 12% growth for the full fiscal, driven primarily by CDMO business, especially from on-patent commercial manufacturing. Its net debt-to-Ebitda ratio improved to 2.7x in FY25 versus 5.6x in FY23.
&w=3840&q=100)
Business Standard
15-05-2025
- Business
- Business Standard
Piramal Pharma expects single-digit growth in FY26 amid uncertainties
PPL projects a muted FY26 due to global headwinds but aims to double its India consumer health business turnover to Rs 2,000 crore by FY30 through scale and expansion Sohini Das Mumbai Listen to This Article Piramal Pharma (PPL), which posted a 12 per cent revenue growth for 2024–25, expects to grow in single digits in the current fiscal with a muted EBITDA. The company has a presence across contract development and manufacturing, complex hospital generics, and a consumer health business in India. Speaking to Business Standard, Nandini Piramal, Chairperson, PPL, said that FY26 is going to be a 'muted year' as there are a lot of uncertainties and it is important to watch out for macro factors like trade deals and tariff environments. PPL posted a 12 per cent rise in revenues to Rs 9,151
Mint
15-05-2025
- Business
- Mint
Piramal Pharma CDMO growth hit by US policy jitters; recovery seen in FY27
Piramal Pharma anticipates muted, single-digit growth for its contract development and manufacturing organization (CDMO) business in FY26, hurt by near-term uncertainties as clients defer decisions amid concerns over US pricing and tariff policies, a top company official said. However, the Mumbai-based firm expects a quick recovery in FY27, and is on track to achieve its target of becoming a $2-billion company with 25% Ebitda (earnings before interest, taxes, depreciation, and amortization) margins by FY30, chairperson Nandini Piramal told Mint. 'There's been an increase in uncertainty and volatility…wher you've got pricing [cuts], whether you've got tariffs, or biotech funding which has been kind of uneven,' Piramal said. 'A lot of customers are pausing on decision-making,' She said, adding that the company has seen an increase in requests for proposals (RFPs) from potential clients. 'They're trying to scenario-play all the options.' A CDMO is a company that provides comprehensive services, from drug development to clinical trials and drug manufacturing to other pharmaceutical and biotech firms on a contract basis. 'In FY27, we should see a significant and a strong recovery,' she added. Earlier this week, Trump signed an executive order to bring down the costs of prescription drugs in the US to match the cheapest global prices. Additionally, he has indicated imposing import tariffs on pharmaceutical products with the view of bringing manufacturing back to US. However, a lot of uncertainty persists over the implementation and details of these orders. Piramal Pharma expects steady growth for its consumer healthcare business and complex hospital generics in the coming year, she said, adding that the company is well-poised to service demand in the CDMO business. 'Once the uncertainty dies down, we have the capacity and the capabilities and one of the best networks in the US, the UK, and India, depending on where our customers want to manufacture their products,' Piramal said. The CDMO business contributed 59% to Piramal Pharma's overall revenues in FY25. Earlier this week, the firm announced a $90 million investment to expand its manufacturing capabilities at two key US facilities - Lexington in Kentucky and Riverview in Michigan. Piramal said that there has been a rise in demand for onshoring post-covid, 'especially for on-patent pharmaceuticals and some of the more complex drugs…to be closer to the customer'. The expansion of the Lexington facility is expected to be completed by calendar year 2027, while the Riverview facility expansion will be completed this calendar year. The company saw significant recovery in FY24 and FY25, with a 14% compounded annual growth rate (CAGR), over 500 bps of Ebitda margin enhancement, and significant improvement in net profits, the company said in an investor presentation. It also brought down its net debt/Ebitda level from 5.6x in FY23 to 2.7x in FY25. 'Over the last couple of years, we've very good growth in our patent innovation-related work in the CDMO business, and that has led to giving us operating leverage and an improvement in Ebitda,' Piramal said. The company expects strong market growth for its India-focused consumer healthcare business, which crossed the ₹ 1,000 crore revenue milestone this year. 'We're also looking at focusing on expanding our distribution from being just a canvas focus in e-commerce, to now broadening to modern trade, quick commerce, stand-alone supermarkets,' Piramal said. For its complex hospital generics business, the company intends to leverage its recently commercialised Sevoflurane facility to expand into the rest of world (RoW) markets. Piramal Pharma currently holds 44% market share for Sevoflurane, an inhaled anaesthetic, in the US. The company expects to expand into other markets inFY26. Sevoflurane has a $400-million global market, Piramal said. The company posted its financial results for Q4FY25 and FY25 on Wednesday. Its revenue grew 8% year-on-year to ₹ 2,754 crore in Q4FY25, and 12% in FY25 to ₹ 9,151 crore, driven primarily by the CDMO business especially from on-patent commercial manufacturing. Ebitda rose 8% year-on-year to ₹ 603 crore in Q4FY25 and 15% YoY to ₹ 1,580 crore in the fiscal year ended 31 March, driven by operating leverage, cost optimization, and operational excellence initiatives, the company said.
&w=3840&q=100)
Business Standard
15-05-2025
- Business
- Business Standard
Piramal Pharma stock falls 5% after Q4 results; check key numbers here
Piramal Pharma share price today: Shares of pharmaceutical firm Piramal Pharma fell around 5 per cent to hit an intraday low of ₹207.95 on Thursday after the company reported its March 2025 quarter (Q4 FY25) results. The stock was down 4.5 per cent at ₹209 compared to the previous day's close of ₹219.04 on the National Stock Exchange (NSE), as of 1:25 PM. In comparison, the benchmark Nifty50 index was trading at 25,073.70 levels, up 406.8 points or 1.65 per cent. Piramal Pharma stock is down over 32 per cent from its 52-week high of ₹307.9, touched on November 6, 2024 Piramal Pharma Q4 results update In Q4 FY25, Piramal Pharma reported consolidated revenue from operations of ₹2,754 crore, up 8 per cent compared to ₹2,552 crore in the year-ago period. The company's earnings before interest, tax, depreciation and amortisation increased 8 per cent year-on-year (Y-o-Y) to ₹603 crore from 556 crore in the year-ago period. Its profit after tax (before exceptional items) stood at 154 crore, up 16 per cent compared to ₹132 crore in the corresponding quarter of the previous fiscal. Piramal Pharma's Ebitda margin remains flat at 22 per cent in the reported quarter. In the CDMO (Contract Development and Manufacturing Organisation) segment, the company's on-patent commercial manufacturing revenues grew by over 50 per cent Y-o-Y to ₹179 million in FY26. Ebitda margins improved on a yearly basis on the back of better procurement strategies, cost optimisation and operational excellence initiatives. "During the year, we progressed well on our key performance metrics such as growth in innovation related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business," said Nandini Piramal, chairperson at Piramal Pharma. About Piramal Pharma Piramal Pharma, a part of Piramal Group, is a pharmaceutical company that offers a range of products and services through its global distribution network in over 100 countries. The company operates 17 global development and manufacturing facilities. Its key businesses include Piramal Pharma Solutions, an integrated contract development and manufacturing organisation; Piramal Critical Care, a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products.
Yahoo
14-05-2025
- Business
- Yahoo
Piramal Pharma Limited Announces Results for Q4 and FY2025
MUMBAI, India, May 14, 2025 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full Year (FY) ended 31st March 2025. Consolidated Financial Highlights (in ₹ Crores or as stated) Particulars Q4FY25 Q4FY24 YoY Growth FY25 FY24 YoY Growth Revenue from Operations 2,754 2,552 8 % 9,151 8,171 12 % CDMO 1,788 1,649 8 % 5,447 4,750 15 % CHG 705 667 6 % 2,633 2,449 8 % ICH 274 238 15 % 1,093 985 11 % EBITDA 603 556 8 % 1,580 1,372 15 % EBITDA Margin 22 % 22 %17 % 17 %PAT (before exceptional item) 154 132 16 % 91 81 13 % Exceptional Item* - (31) NM - (63) NM PAT (after exceptional item) 154 101 52 % 91 18 411 % * Q4FY24 - ₹ 31 Cr towards non-cash write down of investment and license rights in relation to a certain third-party product no longer being commercialized; Q3FY24 - ₹ 32 Cr. related to non-recurring charges towards product recall triggered by a 3rd party supplier Key Highlights for Q4FY25/FY25 Revenue from Operations grew by 8% YoY and 12% YoY in Q4FY25 and FY25 respectively, driven primarily by CDMO business especially from on-patent commercial manufacturing EBITDA grew by 8% YoY and 15% YoY in Q4FY25 and FY25 respectively, on account of operating leverage, cost optimization, and operational excellence initiatives Net-Debt to EBITDA ratio improved to 2.7x Vs. 5.6x in FY23 Best-in-Class Quality Track Record – Continue to maintain our 'Zero OAIs' status since 2011 Sustainability Efforts Yielding Results – Significant enhancement in S&P Global and EcoVadis ESG scores Nandini Piramal, Chairperson, Piramal Pharma Limited said, "FY25 has been a steady year for the company as we crossed $1Bn in revenues with 12% YoY growth accompanied by 17% EBITDA margin and 5x increase in Net Profits, in-line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x, while making regular investments in capabilities and capacities for future growth. During the year, we progressed well on our key performance metrics such as growth in innovation related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business. We believe, we are on track to deliver on our FY2030 aspirations of becoming a $2bn revenue company with 25% EBITDA margins and high teens ROCE." Key Business Highlights for Q4 and FY2025 Contract Development and Manufacturing Organization (CDMO): - Increasing contribution from Innovation1 related work - Up from 50% in FY24 to 54% in FY25, driven by commercial manufacturing of on-patent molecules - Robust growth in on-patent commercial manufacturing revenues - Grew by over 50% YoY to reach $179mn (Vs. $116mn in FY24 and $53mn in FY23) - Revenues from differentiated offerings grew 28% YoY, contributing to 49% of CDMO revenues - Healthy growth in API generics business - YoY improvement in EBITDA margin driven by better procurement strategies, cost optimization and operational excellence initiatives - Maintained our best-in-class quality track record - Successfully cleared 36 regulatory inspections and 165 customer audits in FY25 without any major observations Complex Hospital Generics (CHG): - Inhalation Anesthesia (IA) - Major GPO contract renewal and order wins supporting IA sales in the US. Witnessing encouraging traction in the RoW markets - Capacity expansion in India completed and commercialized on time; poised to capitalize on ~US$400 mn2 Sevoflurane market opportunity in the RoW markets - Maintained our #1 Rank in the US in Sevoflurane (44% market share2) and in intrathecal Baclofen (75% market share2) - Received approval for Neoatricon®3 for multiple markets in EU and UK by our partner BrePco Pharma. Neoatricon® is the only pre-diluted, age-appropriate formulation of dopamine, approved for treating children and infants - Moderation in EBITDA margins due to some non-recurring expenses and capacity expansion in India. However, recovery expected from FY26 with commercialization of these added capacities India Consumer Healthcare (ICH): - ICH business crossed the strategic revenue milestone of ₹ 1,000 crores during the year - Power Brands continue to grow strength to strength with 20% YoY during FY25. Power Brands contributed to 49% of total ICH sales o Excluding i-range, which was impacted by regulatory price control, growth in power brands was about 26% in FY25 - New Product Launches - Added 21 new products and 31 new SKUs in FY25 - Investments in Media and Promotions – 11% of ICH sales in FY25. Launched our new media campaign with Yami Gautam for Little's - E-commerce sales grew at 39% YoY in FY25, contributing 21% to ICH sales,. Present on more than 20 e-commerce platforms 1. Discovery + Development + Commercial Manufacturing of products under patent; 2. As per IQVIA data, September 2024; 3. Neoatricon® is developed by BrePco Biopharma; we have secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing in these regions. Consolidated Profit and Loss Statement (in ₹ Crores or as stated) Particulars Quarterly Full Year Q4FY25 Q4FY24 YoY Change FY25 FY24 YoY Change Revenue from Operations 2,754 2,552 8 % 9,151 8,171 12 % Other Income 42 26 59 % 135 175 (23 %) Total Income 2,796 2,579 8 % 9,286 8,347 11 % Material Cost 955 1,014 (6 %) 3,232 2,954 9 % Employee Expenses 612 494 24 % 2,307 2,030 14 % Other Expenses 626 514 22 % 2,167 1,991 9 % EBITDA 603 556 8 % 1,580 1,372 15 % Finance Cost 104 114 (9 %) 422 448 (6 %) Depreciation 243 196 24 % 816 741 10 % Share of net profit of associates 16 12 35 % 73 59 23 % Profit Before Tax 273 258 6 % 415 242 71 % Tax 119 126 (5 %) 324 161 100 % Net Profit after Tax (before exceptional item) 154 132 16 % 91 81 13 % Exceptional item* - (31) NM - (63) NM Net Profit after Tax (after exceptional item) 154 101 52 % 91 18 411 % * Q4FY24 - ₹ 31 Cr towards non-cash write down of investment and license rights in relation to a certain third-party product no longer being commercialized; Q3FY24 - ₹ 32 Cr. related to non-recurring charges towards product recall triggered by a 3rd party supplier Consolidated Balance Sheet (In ₹ Crores) Key Balance Sheet Items As at 31-Mar-25 31-Mar-24 Total Equity 8,125 7,911 Net Debt 4,199 3,932 Total 12,324 11,843Net Fixed Assets 9,110 9,106 Tangible Assets 4,534 4,250 Intangible Assets including goodwill 3,599 3,740 CWIP (including IAUD*) 977 1,116 Net Working Capital 2,798 2,339 Other Assets# 416 398 Total Assets 12,324 11,843 *IAUD – Intangible Assets Under Development # Other Assets include Investments and Deferred Tax Assets (Net) Q4FY25/FY25 Earnings Conference Call Piramal Pharma Limited will be hosting a conference call for investors / analysts on 15th May 2025 from 9:30 AM to 10:15 AM (IST) to discuss its Q4 and FY25 Results. The dial-in details for the call are as under: Event Location & Time Telephone Number Conference call on 15th May, 2025 India – 09:30 AM IST +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) 1 800 120 1221 (Toll free number) USA – 12:00 AM (Eastern Time – New York) Toll free number 18667462133 UK – 05:00 AM (London Time) Toll free number 08081011573 Singapore – 12:00 PM (Singapore Time) Toll free number 8001012045 Hong Kong – 12:00 PM (Hong Kong Time) Toll free number 800964448 Express Join with Diamond Pass™ Please use this link for prior registration to reduce wait time at the time of joining the call – Click Here About Piramal Pharma Limited: Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. * Includes one facility via PPL's minority investment in Yapan Bio. For more information, visit: Piramal Pharma | LinkedIn Logo - View original content: SOURCE Piramal Pharma Ltd View original content:
